A comparison of the effects of hydromorphone HCl and a novel extended release hydromorphone on arterial blood gas values in conscious healthy dogs.
The purpose of this study was to evaluate arterial blood gases in dogs that were given hydromorphone or extended release liposome-encapsulated hydromorphone (LEH). Dogs were randomly administered LEH, n=6, (2.0 mg kg(-1)), hydromorphone, n=6, (0.2 mg kg(-1)) or a placebo of blank liposomes, n=3, subcutaneously on separate occasions. Arterial blood samples were drawn at serial time points over a 6-h time period for blood gas analysis. There was no change from baseline values in P(a)CO(2), P(a)O(2), (HCO(3)-), pH, and SBEc in the dogs that received the placebo. Administration of hydromorphone resulted in significant increases in P(a)CO(2) (maximum (mean+SD] 44.4+1.1mm of Hg) and significant decreases in P(a)O(2) (minimum (mean+SD) 82.4+4.7 mm of Hg) and pH (minimum (mean+SD) 7.31+0.01) compared with baseline. Administration of LEH resulted in significant increases in P(a)CO(2) (maximum (mean+SD) 44.6+0.9 mm of Hg) and significant decreases in P(a)O(2) (minimum (mean+SD) 84.8+2.6mm of Hg) and pH (minimum (mean+SD) 7.34+0.02) compared with baseline. There was no significant difference between these two groups at any time point. The changes observed in P(a)CO(2), P(a)O(2), and pH, however, were within clinically acceptable limits for healthy dogs. LEH was determined to cause moderate changes in arterial blood gas values similar to those caused by hydromorphone.
Wunsch
L A
LA
Department of Surgical Sciences, University of Wisconsin, Madison, WI 53706, USA. smithl@svm.vetmed.wisc.edu
Schmidt
B K
BK
Krugner-Higby
L A
LA
Smith
L J
LJ
D000698:Analgesia / Q000662:veterinary; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D000818:Animals; D001784:Blood Gas Analysis / Q000662:veterinary; D002245:Carbon Dioxide / Q000097:blood; D003692:Delayed-Action Preparations; D004285:Dogs; D006863:Hydrogen-Ion Concentration; D004091:Hydromorphone / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D008297:Male; D010100:Oxygen / Q000097:blood; D012131:Respiratory Insufficiency / Q000139:chemically induced
D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D002245:Carbon Dioxide; D004091:Hydromorphone; D010100:Oxygen
Clin J Oncol Nurs. 2007 Apr;11(2):293-6
17573279
J Am Vet Med Assoc. 2003 Feb 1;222(3):330-6
12564595
J Vet Pharmacol Ther. 2008 Dec;31(6):580-3
19000282
Anesth Analg. 2000 Jun;90(6):1359-64
10825321
J Appl Physiol. 1972 Jan;32(1):152-3
5007010
Vet Anaesth Analg. 2008 May;35(3):256-64
18282253
Vet Clin North Am Small Anim Pract. 2000 Jul;30(4):757-72
10932823
J Pain Palliat Care Pharmacother. 2007;21(1):63-6
17430835
Drug Saf. 1992 May-Jun;7(3):200-13
1354445
Vet Anaesth Analg. 2006 Mar;33(2):111-21
16476001
Am J Vet Res. 2004 Jul;65(7):931-7
15281651
Palliat Med. 2007 Mar;21(2):81-6
17344255
Can Vet J. 2000 Feb;41(2):135-7
10723604
J Am Vet Med Assoc. 2001 Apr 1;218(7):1101-5
11318359
Br J Anaesth. 2004 Aug;93(2):212-23
15169738
Support Care Cancer. 2008 Jan;16(1):93-9
17929063
J Vet Pharmacol Ther. 2008 Oct;31(5):415-22
19000260
Vet Surg. 1996 Jul-Aug;25(4):361-9
8810028
Am J Vet Res. 2008 May;69(5):586-95
18447788
Addiction. 1999 Jul;94(7):961-72
10707430
Am J Vet Res. 1987 Nov;48(11):1626-30
2449102
Am J Vet Res. 1986 Feb;47(2):471-4
2420241
Clin Pharmacokinet. 2006;45(11):1051-60
17048971
J Vet Pharmacol Ther. 2004 Oct;27(5):369-72
15500576